Podcasts about Mirasol

Stephanie Poynor is a Tampa community leader and President of the Tampa Homeowners Association of Neighbors (THAN), known for her deep involvement in land use, city council hearings, and advocating for neighborhood voices in development decisions.0:01:39 - THAN0:24:22 - Transportation0:35:39 - Developers vs. Neighbors0:44:06 - Traffic0:56:28 - Tampa Rays1:16:35 - Storm Water Service1:39:00 - THAN's Goal1:46:40 - Tampa's Future2:01:52 - Affordable Housing2:12:43 - Mirasol

Howard Hamilton previews all 16 matches from Match Day 2 of the 2025 Copa Libertadores group stage, with the top two seeds playing their first home matches of the competition. Featured matches include Flamengo hosting Independiente Medellín at the Maracanã, Boca Juniors welcoming Barcelona SC to La Bombonera in a storied Libertadores rivalry, and Liga de Quito hosting Mirasol in a battle of Match Day 1 winners at altitude in Quito.Howard also breaks down key suspension news across the groups, including absences for Platense, Corinthians, Cerro Porteño, Independiente del Valle, and Bolívar, and previews a Group F clash between Palmeiras and Sporting Cristal that follows one of the most lopsided results in recent Libertadores history. All 16 matches can be followed on Fanatiz, Fubo Sports, or YouTube. The SoccerMetrics Copa Libertadores Show is proudly part of the SDH Network, the home of English-language coverage of South American soccer. Send questions and comments to @SoccerMetrics on X.

Frank & Lindsey Carriera break down the complex effort to preserve the Mirasol, a 100 year old landmark on Davis Islands, and explain why restoring historic buildings is far more complicated than new construction. They discuss storm damage, resiliency challenges, community feedback, and the long process of adapting an aging structure to modern needs without losing its character. This episode explores how preservation, economics, and neighborhood concerns intersect as Tampa continues to grow.0:00:00 - Intro0:06:03 - Mirasol's History0:11:17 - Redevelopment0:37:53 - Mirasol Restaurant0:43:46 - Community0:58:22 - Preservation 1:07:18 - Outro

Jerel McCants, the architect leading the rebuilding of the Jackson House and the renovation of Tampa Union Station, breaks down the broader design, development, and preservation issues shaping Tampa's built environment. He discusses how architectural decisions influence communities, the challenges of restoring historic structures, the pressures created by rapid growth, and the importance of protecting culturally significant places. This episode takes a clear look at how Tampa's past and future meet through thoughtful design and redevelopment.0:00:00 - Intro0:03:33 - Streetscapes0:14:39 - Mixed-Income Housing0:22:38 - Encore0:38:51 - Old West Tampa0:48:55 - Jackson House1:09:15 - Mirasol, Davis Islands1:17:57 - Union Station1:40:39 - Jerel McCants Book1:46:03 - Permitting1:51:48 - Over-developing Florida2:03:13 - Outro

Apertem os cintos, porque o PPcast viajou no tempo e mergulhou nas estratégias de marketing mais quentes da semana!

En esta cápsula de ESMO 2025 EXPRESS, el Dr. Gonzalo Giornelli, oncólogo clínico y jefe del Departamento de Gineco-Oncología del Instituto Alexander Fleming en Buenos Aires, Argentina, nos comenta brevemente los avances más relevantes en tumores ginecológicos presentados durante el congreso ESMO 2025.El gran protagonista de este ESMO fue, sin duda, el cáncer de ovario, particularmente en el contexto platino-resistente, una población de mal pronóstico y con necesidad de nuevas alternativas terapéuticas. En este escenario, tres estudios marcaron un antes y un después al demostrar beneficios en sobrevida global.El primero, KEYNOTE-B21, evaluó pembrolizumab más paclitaxel semanal ± bevacizumab frente al estándar de paclitaxel ± bevacizumab. Este estudio mostró una reducción del riesgo de progresión del 28 % y una disminución del riesgo de muerte del 24 %, con un incremento notable en la tasa de respuesta (50 % vs 40 %). El Dr. Giornelli subraya que este régimen se consolida como una nueva opción sin necesidad de selección por PD-L1, aunque advierte que la población estudiada tuvo menor exposición a inhibidores PARP que la práctica actual. Estos resultados llevaron a la aprobación acelerada por la FDA como nuevo estándar en pacientes con cáncer de ovario platino-resistenteEl segundo estudio mencionado fue MIRASOL, con el anticuerpo conjugado mirvetuximab soravtansine, que demostró una reducción del 37 % en el riesgo de progresión y del 32 % en el riesgo de muerte, junto con tasas de respuesta del 42 %. Sin embargo, requiere la sobreexpresión del receptor de folato alfa, presente en alrededor del 36 % de las pacientesEn otras patologías ginecológicas, el Dr. Giornelli resaltó un estudio chino en cáncer de cérvix, que evaluó camrelizumab + famitinib (una combinación similar a pembrolizumab + lenvatinib) frente a quimioterapia sola, mostrando beneficios en PFS, OS y tasa de respuesta, aunque con toxicidades relevantes.Finalmente, en cáncer de endometrio, destacó que se avanza hacia una mayor precisión molecular para definir tratamientos en pacientes sin alteraciones MSI-H o POLE. Además, subrayó la importancia de identificar el subgrupo HER2 positivo, dada la alta tasa de respuesta (> 76 %) observada con trastuzumab deruxtecán en este grupo.El especialista concluye que ESMO 2025 marcó un punto de inflexión en oncología ginecológica, con tres nuevas alternativas terapéuticas para cáncer de ovario platino-resistente y múltiples desarrollos en cáncer de cérvix y endometrio, reafirmando la relevancia de la inmunoterapia y los ADCs como ejes del futuro tratamiento en estos tumores

Tampok sa mga bagong balita sa Pilipinas mula flood-control projects, bagong bayong at pagtatapos ng termino ng Chinese Ambassador to the Philippines.

Die Ärztin Dr. Eva Mirasol rappt über den Pflegenotstand und hat gerade einen unterhaltsamen Roman über den alltäglichen Wahnsinn in einer Rettungsstelle veröffentlicht. Warum man bei Wiederbelebung nichts falsch machen kann und wie wichtig Humor in stressigen Momenten ist, erzählt sie bei Thorsten Otto.

Eva Mirasol ist Ärztin, die irgendwann das Schreiben und auch die Bühne für sich entdeckt hat. Sie hat Kolumnen geschrieben und ist Mitglied mehrerer Lesebühnen in Berlin. In ihrem ersten Roman „Staying alive – kein Arztroman“ geht es um den alltäglichen Wahnsinn in der Notaufnahme eines Krankenhauses. Hier erzählt Eva über ihre erste Nachtschicht, die so ganz anders gelaufen ist, als sie sich das gedacht hatte. Denn plötzlich war ein Patient weg. Es geht außerdem um die schlechten Bedingungen in den deutschen Notaufnahmen und darum, was wirklich helfen würde. Und sehr amüsant auch: ihre Suche nach einem gut anwendbaren Begriff für das weibliche Geschlechtsteil. Denn „Scheide“ kann es ja nun wirklich nicht sein, meint Eva. Podcasttipp „Die Ernährungs-Docs – Essen als Medizin“: https://www.ardaudiothek.de/sendung/die-ernaehrungs-docs-essen-als-medizin/urn:ard:show:c9684369f9824d59/

Matt Lambert, General Manager/COO of The Country Club at Mirasol, and Tim Rayman, CEO of Greenleaf Hospitality Group and General Manager of Kalamazoo (Mich.) Country Club, join Rob Thomas on the Club + Resort Talks podcast. Lambert was named the 2025 Facility Manager of the Year by the Racquet Sports Professional Association (RSPA), Florida Division. This prestigious award recognizes facility leaders who demonstrate exceptional commitment to the advancement of racquet sports within their facilities and the professionals who support them. Tim Rayman discusses the extensive renovations at the Kalamazoo Country Club. The club, founded in 1909, is undergoing significant changes, including a new 11-hole short course designed by Andrew Green, set to open in Q1 2026. The new clubhouse will feature two restaurants, a 34-seat movie theater, a six-lane bowling alley, and multiple pools. Additionally, a new 18-hole championship course will be built on the existing 145 acres. The project aims to enhance member retention and recruitment by offering a wide range of amenities, including a golf Performance Center with advanced teaching technology. Also in the news ... A full remodel is underway at Desert Highlands to include enhanced lighting and expansive entrance in the golf shop, as well as self-serve comfort stations in the locker room. The Country Club of Whispering Pines and Foxfire Golf Club in the Sandhills of North Carolina have been acquired by Rolling Pines LLC, a newly formed management concern with the parent company of Mid Pines Development Group. KemperSports acquired Fire Pit Productions and named Matt Ginella Chief Storyteller, while also launching Youth Golf Week to inspire young players and grow the game through stories and community. And, Scarecrow, designed by David McLay Kidd, will open for public play on August 1. The course plays to a par of 71, stretches to 6,900 yards and is turfed with traditional fine fescue, which provides for firm and fast surfaces.

Escuchá el relato del gol de Jourdan ante el Mirasol

Zu viel Promille und eine Platzwunde am Kopf, wenig Schlaf und quasi immer unterbesetzt – das ist die Realität, die Eva Mirasol aus der Notaufnahme eines Krankenhauses zeichnet. Als "alles außer alltäglichen Alltag" beschreibt die 43-Jährige in ihrem ersten Roman die Arbeit in der Ambulanz eines Klinikums. Mirasol, die mit ihrer Familie in Berlin lebt und bereits Kolumnen für die taz und Texte für die Zeitschrift der Berliner Ärztekammer schrieb, muss es wissen: Denn sie ist nicht nur Autorin, sondern auch Fachärztin für Innere Medizin und hat früher selbst in der Notaufnahme gearbeitet. Wie man mit dem permanenten Ausnahmezustand in einer ambulanten Notaufnahme zurechtkommt und wieviel eigene Erfahrung sie in ihrem Erstlingswerk verarbeitet hat, erzählt sie bei ihrem ersten Talkshowbesuch an der Weser.

Rebranding a nonprofit isn't just about new logos or fresh colors—it's an emotional journey deeply rooted in the mission, culture, and service commitment of an organization. James Dismond, CEO of Mirasol Health, formerly Hospice Care of the Low Country, joined host Julia Patrick to share the inspiring, often emotional, details of their transformative rebranding.For decades, Hospice Care of the Low Country was a dedicated nonprofit, caring for patients facing end-of-life scenarios. Yet, despite their essential services, the organization faced an existential challenge: staying relevant in an evolving healthcare landscape. A candid internal study revealed a stark truth: if no changes were made, they faced closure within five years.James vividly recalls the moment that changed his personal and professional trajectory. On his very first day, several patients passed away, confronting him directly with his deepest fear—death. Instead of turning away, he embraced this fear, turning it into a profound passion. James noted, “That fear has since transcended into my greatest passion, and I'm very blessed for that.”The rebranding initiative was far from simple. It was two years in the making, involving rigorous strategic analysis, extensive stakeholder consultations, and an honest assessment of community perceptions. The word “Hospice” was a significant barrier, fraught with fear and misunderstanding. This realization was a pivotal turning point. James explains, "The powerful messages we are getting back just touch my heart every single day."Ultimately, the staff themselves coined the new name, “Mirasol,” symbolizing "rare and radiant sunflower," beautifully capturing the legacy and spirit of the organization's enduring symbol—the sunflower. This rebranding was not merely aesthetic; it expanded the scope of services, adding chronic symptom management and soon behavioral health, significantly broadening their community impact.The process brought substantial internal shifts, compelling deep introspection and alignment from the board, leadership, and staff. It was emotionally challenging but profoundly rewarding, significantly boosting community engagement, donations, and overall business performance.Today, Mirasol Health stands as a vibrant example of successful nonprofit transformation, rooted in authenticity and courage. “If you do the research, the strategy, and deliver it thoughtfully, the payoff is truly incredible.”#NonprofitRebrand #CommunityHealth #ChangeLeadershipFind us Live daily on YouTube!Find us Live daily on LinkedIn!Find us Live daily on X: @Nonprofit_ShowOur national co-hosts and amazing guests discuss management, money and missions of nonprofits! 12:30pm ET 11:30am CT 10:30am MT 9:30am PTSend us your ideas for Show Guests or Topics: HelpDesk@AmericanNonprofitAcademy.comVisit us on the web:The Nonprofit Show

On this episode, we are thrilled to be talking to the 2024 Club Executive of the Year, Matt Lambert, CCM, CCE, CAM. In November, Club Management magazine named Matt Lambert the 2024 Club Executive of the Year. He currently serves as the General Manager/Chief Operating Officer of The Country Club at Mirasol in Palm Beach Gardens, FL. Lambert has more than 24 years of experience in the club industry. Get to know Matt in this episode!

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Robert Coleman to discuss overall survival of SORAYA trial. Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. From 1993-1996, he served as Assistant Professor at Creighton University followed by service as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center. Dr. Coleman joined as Faculty at MD Anderson Cancer center in 2004 and served as Professor and Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research (USOR) as Chief Scientific Officer and served briefly as Chief Medical Officer for Sarah Cannon Research Institute (SCRI). He currently serves as Chief Medical officer for Vaniam Group. Dr. Coleman has authored or coauthored over 750 scientific publications, including over 450 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. He was the 2019 APGO-CREOG awardee for Excellence in Teaching. He serves as Vice President of GOG-Foundation, Inc. He served as President of SGO (2015-2016) and is the immediate Past-President of IGCS. He was recently inducted into MJH Life Sciences™ 2020 class of “Giants in Cancer Care®.”   Highlights: Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate comprising an  FRα-binding antibody, cleavable linker, and maytansinoid DM4, a potent tubulin-targeting agent Early clinical data suggested efficacy in recurrent platinum-resistant ovarian cancer (PROC) prompting a larger trial to confirm both safety and efficacy in patients with PROC In this SORAYA trial MIRV demonstrated clinically meaningful antitumor activity in patients with FRα-high platinum-resistant ovarian cancer with an ORR: 32.4% and a median DOR: 6.9 months Remarkably the median OS was 15 months; 37% patients alive at 24 months Efficacy of MIRV was further evaluated with respect to when it was administered (as first treatment for PROC) and in patients receiving prior bevacizumab.  An ORR of 34.8% was documented in the formers, and 31.5% in the latter. The ocular toxicity was new for many treating physicians when the drug first became available. However with mitigating strategies as used in the study the events were predictable, low-grade, and rarely (n=1 patient) led to treatment discontinuation Now with MIRASOL confirming these data and demonstrating efficacy over standard of care for response, PFS, and unprecedently, OS, the agent is a staple of contemporary management.

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancerRUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancerSurvival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancerDUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancerLong-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatinSubgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator's choice of chemotherapy in FR

On the latest episode of Club + Resort Talks, Editor-In-Chief Rob Thomas and Senior Editor Phil Keren reviewed a variety of projects happening in multiple spots across the country. Plus, what could go wrong with the name Buchholz in Closed Captioning? Rob and Phil discussed a yacht club reopening after being destroyed by a hurricane, an $82 million renovation project at a Florida club, an effort to restore the oldest public golf course in Wisconsin and the reopening of a California golf club that was once the site of Skins Game tournaments in the 2000s. Gulf Harbour Yacht & Country Club in Fort Myers, Fla. has reopened after being destroyed by Hurricane Ian in late 2022. Golden Marine Systems recently completed Phase 1 of Gulf Harbour's renovation project, 18 months after the devastating storm. This project includes 101 new slips to accommodate vessels up to 88 feet long. The Country Club at Mirasol in Palm Beach Gardens, Fla. is undergoing an $82 million multi-year enhancement project. The upgrade work, which was recently approved by the club's membership, is part of the second phase of the Mirasol Master Plan, a long-term, strategic vision for the advancement of the 20-year-old facility. Work is happening to restore the Tuscumbia Golf Course in Green Lake, Wis., the oldest public golf course in the state. In the spring of 2023, Rusty Grimm and Eric Buchholz acquired Tuscumbia Golf Course from John Geils and the Tuscumbia Land Corp., who had owned the property for 14 years. Significant improvements have been made under Buchholz's guidance, including greens restoration, overall landscaping, and the reopening of the course's pro shop. However, the restoration process is ongoing. The goal is to have 18 smooth and fast putting surfaces by the end of the season, alongside numerous smaller projects to enhance the clubhouse's appearance and efficiency. Coral Mountain Golf Club in La Quinta, Calif. Closed in 2022. Earlier this year, the residents of Trilogy at La Quinta voted overwhelmingly to purchase the golf course, clubhouse and restaurant. Those members reverted the club back to its original name, Trilogy Golf Club at La Quinta, and have invested in a multi-million-dollar renovation to modernize the facilities. The homeowners have even brought back the original management team from BlueStar Resort & Golf to oversee the renovation and manage the club. Lastly, Horseshoe Bay (Texas) Resort added new lighting, and food and drink options to its Whitewater Putting Course to make the engaging, par-72 loop more fun for all ages. The sand in the bunkers has been replaced with a vibrant crushed marble sand, as well, that contrasts beautifully with the smooth-rolling Zoysia grass.

El restaurant can

Talked with Barbara Abernathy, CEO, Pediatric Oncology Support Team (P.O.S.T.).  They have been providing support for families with children who are receiving cancer treatment for twenty-six years.  "POST provides counseling services, case management, financial crisis stabilization, support groups, hospital visits, educational planning, services for siblings and bereavement care."  The services are 100% free for families who have a child diagnosed with cancer. For more info listeners can call 561-882-6336 or go to POSTFL.org.  One of their big fundraisers is POST Gold Ribbon Heroes Luncheon on May 7th from 11:30am to 2pm at the Country Club at Mirasol.  This year's event is Mother's Day themed and will honor moms who have a child battling cancer.  There are auction items, wine raffle and a young ambassador who's been fighting Neuroblastoma stage IV for over 2 years. Tickets are $200 and can be purchased online.  You can also sponsor someone else's seat, volunteer to help, or make a donation at www.postfl.org.

Nascentmc.com for medical writing assistance for your company. Visit nascentmc.com/podcast for full show notes Visit learnAMAstyle.com for free downloads regarding editing and the AMA Manual of Style tip sheet.  Nexletol and Nexlizet for LDL Lowering and CV Risk: The FDA approved bempedoic acid (Nexletol) and its combination with ezetimibe (Nexlizet) for reducing cardiovascular risk and treating primary hyperlipidemia. Bempedoic acid inhibits a cholesterol synthesis enzyme, while ezetimibe blocks cholesterol absorption, both lowering LDL-C levels. The approval, for high-risk patients not yet having cardiovascular events, was based on the CLEAR Outcomes trial. Iclusig for ALL: The FDA granted accelerated approval to ponatinib (Iclusig) with chemotherapy for treating previously untreated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ponatinib, a tyrosine kinase inhibitor, is the first targeted agent for this leukemia type in combination with chemotherapy, based on the PhALLCON trial results. Further confirmatory data may be required to verify its clinical benefit. Elahere for Ovarian Cancer: Mirvetuximab soravtansine-gynx (Elahere) received FDA approval for treating folate receptor alpha-positive, platinum-resistant ovarian cancer, marking it as the first antibody-drug conjugate in the U.S. for this condition. The treatment targets cancer cells by binding to the folate receptor alpha, delivering a cytotoxic agent. Approval was based on the Phase 3 MIRASOL trial. Duvyzat for DMD: The FDA approved givinostat (Duvyzat) for patients 6 years or older with Duchenne muscular dystrophy (DMD), a rare neuromuscular condition. Givinostat is an HDAC inhibitor that mitigates muscle damage and slows disease progression. Approval was based on the EPIDYS trial results, granted to Italfarmaco S.p.A. Spevigo for Psoriasis: Spesolimab-sbzo (Spevigo) received FDA approval for treating generalized pustular psoriasis (GPP) in adults and pediatric patients, expanding its indication from initial approval for GPP flares. As the first targeted therapy for GPP, it acts as an IL-36 receptor antagonist. The expanded approval was based on the Effisayil 2 trial, showing significant reduction in GPP flares. Tryvio for Hypertension: The FDA approved aprocitentan (Tryvio) in combination with other antihypertensive drugs for adults not adequately controlled on other medications, marking it as the first new oral antihypertensive therapy pathway in nearly 40 years. Based on the PRECISION trial, aprocitentan was shown to be effective in patients with resistant hypertension. Opsynvi for PAH: Macitentan and tadalafil (Opsynvi) was approved by the FDA for adults with pulmonary arterial hypertension (PAH) and WHO functional class II-III, as the first once-daily single-tablet combination therapy for PAH. The approval was based on the A DUE study, demonstrating greater reduction in pulmonary vascular resistance compared to monotherapies. Lenmeldy for Juvenile Metachromatic Leukodystrophy: The FDA approved Lenmeldy (atidarsagene autotemcel) gene therapy for children with metachromatic leukodystrophy (MLD), a rare genetic disease affecting the brain and nervous system. The therapy uses the patient's own genetically modified stem cells to produce the missing enzyme. Approval was based on significant improvements in survival, mobility, and cognitive functions observed in clinical trials and an expanded access program.

Cabin Steward Arrested Over Hidden Cameras is the lead story on Wednesday's Travel and Cruise Industry News Podcast, March 6, 2024 with Chillie Falls. 34-year-old Arvin Joseph Mirasol, A Royal Caribbean Cabin Attendant from the Philippines, was arrested in Fort Lauderdale when Symphony of the Seas returned from her most recent cruise. Mirasol allegedly placed hidden cameras in a number of staterooms. Also today, Post Dry-dock Carnival Sunrise; Job Opening To Test Casino; Around The World In 180 Days; Utopia Sooner Than Plans; Passenger Sues Over Donkey Injury; and Lots More LIVE at 11 AM EST. CLICK HERE to access video feed #wednesdaytravelandcruiseindustrynews #podcast #cruisenews #travelnews #cruise #travel #chilliescruises #chilliefalls Thanks for visiting my channel. Travel Hacker's Toolkit https://bit.ly/travelhackertools NYTimes The Daily, the flagship NYT podcast with a massive audience. "Vacationing In The Time Of Covid" https://nyti.ms/3QuRwOS To access the Travel and Cruise Industry News podcast; https://cms.megaphone.fm/channel/trav... or go to https://accessadventure.net/ To subscribe: http://bit.ly/chi-fal As always, I appreciate super chats or any other donation to support my channel. For your convenience, please visit: https://paypal.me/chillie9264?locale.... Chillie's Cruise Schedule: https://accessadventure.net/chillies-... For your special needs, contact me, or Whill.inc/US, at (844) 699-4455 .or Scootaround, For information on cruises, or special needs travel, contact me or Incredible Memories Travel Check out my streaming partner: https://streamyard.com?pal=4889083533852672 YouTube: https://www.youtube.com/@ChilliesCruises Facebook: https://www.facebook.com/chillie.falls Twitter: https://twitter.com/ChillieFalls Instagram: https://www.instagram.com/chilliefalls/ TikTok: https://www.tiktok.com/@chilliescruises Business Email: chillie@chilliefalls.com Accessible Travel Blog: https://accessadventure.net/ Chillie Chats With Sue Bryant, London Times Cruise Editor About Emerald Azzurra https://youtu.be/_bnrkqPf2gE Chillie Chats With Disability Advocate Kristy Durso https://youtube.com/live/YNyiUDyW82o Chillie Chats with Sylvia Longmire, Ambassador for Scootaround and WHILL Powerchairs https://youtu.be/VovRJ5Fh1I8 Chillie Chats With Ali Ingersoll, disability advocate and 2023 Ms Wheelchair America https://youtu.be/o31zOMYYqiw Chillie Chats With Special Guest Kevin Martin, 30 And A Wake Up https://youtube.com/live/7Q5AFPDD0YY Chillie Chats with Mark Chilutti on Accessibility of Oasis of the Seas https://youtu.be/ibuJe7sfvrA Chillie Chats With Kelly Narowski, Disability Rights Advocate and Avid Traveler https://youtube.com/live/YKzSpi8jdB0 Casino Loyalty Programs with Sue Sherer https://youtu.be/p0SsewJC_cE Learn more about your ad choices. Visit megaphone.fm/adchoices

durée : 00:02:49 - Il y a un an, la Villa Mirasol recevait sa première étoile

Lucas Laguna, Intendente de Mirasol, pasó por el aire de Radio 5 hablo sobre la actualidad que se vive hoy en la vecina localidad, con un presupuesto acotado y priorizando situaciones para dejar en espera a muchas otras que hoy no se pueden atender. En diálogo con el intendente de la localidad, expresó, “estamos tranquilos, yo creo que la orden del gobernador es esa, tratar de ser bastante austeros en lo que hagamos, asegurarnos que la gente cobre los sueldos, tenga alimentos y atención en salud, para que ningún pampeano se quede sin comer y sin ser atendidos en la salud pública. Yo vengo de ser secretario en la gestión anterior, y las cosas cambiaron mucho porque hay muchos menos ingresos, la gente prioriza comer a pagar un impuesto y uno tiene que hacer un poco de magia para poder llevar todo esto adelante”. El estado por lo general toma intervención de alguna manera en distintas instituciones o con obras que benefician a toda la localidad, pero en la actualidad esto ya no sucede. “La gente no toma dimensión de la buena intervención que hay del estado diariamente, independientemente del nivel económico de cada persona. Todos accedemos a un montón de cosas del estado. La cancha de pádel fue iniciativa de la municipalidad e inversión 100% de la municipalidad, terminamos de hacer la cancha y automáticamente se la donamos al club Belgrano para que saque un rédito económico de esa cancha, y hoy en día el club tiene una buena entrada económica desde esa cancha de pádel”. Algunos tienen expectativa por que la situación mejore y otros no ven la luz al final del túnel. Por su parte Lucas expresó, “yo deseo que se acomode, siempre fui optimista pero no le veo un rumbo. Nadie quiere la debacle total para arrancar de cero, hay que meterle optimismo y pensar que eso no va a pasar. Yo personalmente no le veo ninguna salida con las medidas que está tomando, principalmente porque todas van en contra de la gente trabajadora”.       

Lucas Laguna, Intendente de Mirasol, pasó por el aire de Radio 5 para hablar sobre los carnavales que llegan este sábado 3 de febrero a la vecina localidad, con sus clásicas carrozas, batucadas y buena música para disfrutar del fin de semana. En diálogo con Lucas expresó, “Venimos trabajando, las instituciones respondieron y vamos a tener un importante numero de carrozas. Reciclamos algunas para poder hacer el carnaval con esta situación complicada, intentando llevarle un poco de alegría a la gente de todas maneras”. De la jornada participarán Fer Pereyra con su show y cierra la noche Kevin Fest en el escenario principal. Además, estará el clásico desfile de carrozas, que preparó cada institución. “Cada uno tiene amor por una institución y cuando una se pone a trabajar todos se enganchan. Hay que predicar con el ejemplo y nosotros estamos haciendo dos carrozas en conjunto con toda la gente que quiso colaborar, y es la mejor manera de incentivar a la gente. Estamos todos los días trabajando en el corralón municipal. Hay gente que nos lleva algún fierrito para soldar de su carroza porque no tiene soldador y es una forma de lograr hacer esto que tanto nos gusta”. Además, estará la batucada “Los Legendarios y habrá una especial participación, de una batucada conformada por los jóvenes que asistieron este verano al Pro Vida. A su vez, la cantina estará a cargo del Club Social y Deportivo Belgrano. La entrada tiene un valor de $1000.       

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research in gynecologic cancers [2:06], multiple myeloma [9:15], and head and neck cancer [16:03]. First, Dr. Lan Coffman discusses new research in ovarian cancer, uterine cancer, and cervical cancer. Dr. Coffman is a physician-scientist and gynecologic oncologist at the Magee-Womens Research Institute and Foundation, and assistant professor in Hematology-Oncology at the University of Pittsburgh School of Medicine. She is also the 2023 Cancer.Net Associate Editor for Gynecologic Cancers. You can view Dr. Coffman's disclosures at Cancer.Net. Dr. Coffman: Hi, my name is Lan Coffman. I'm a physician-scientist at the University of Pittsburgh. I'm a medical oncologist that specializes in gynecologic cancers, and I'm happy to discuss research that was presented on gynecologic cancers at the 2023 ASCO Annual Meeting. I do have a relevant disclosure. I participated in one of the trials I'm going to discuss, a trial called MIRASOL. I was the site principal investigator at University of Pittsburgh. I think there were a lot of interesting studies to highlight, and I wanted to focus on studies involving ovary cancer, endometrial cancer, and cervix cancers as the main sites that we study in the gynecologic oncology world. So when we talk about ovary cancer, I think there was one really impactful study that was presented at ASCO this year, and it was called MIRASOL. And again, this is the study that I also participated in at our hospital at University of Pittsburgh. So it was a large study, so a randomized phase 3 study looking at a drug called mirvetuximab, which is an antibody-drug conjugate. So basically, it's an antibody against a protein that is expressed on ovarian cancer cells and the protein's called folate receptor-alpha. And that antibody basically carries a little poison. And so it's kind of like a Trojan horse. This antibody goes, finds that protein on the tumor cells, and then delivers that poison. And so this drug has been studied and actually was presented last year in a different trial called SORAYA, which showed that it had activity, meaning the drug helped to kill ovarian cancer cells, and actually led to the first approval of this drug in ovary cancer. So this trial was the confirmatory trial, so enrolling more patients to see, actually, is it better than standard-of-care chemotherapy? So this was in women with ovarian cancer that had come back and was platinum resistant, meaning the cancer started to grow within 6 months from the last platinum-based therapy. Women were eligible if they had high expression of this folate receptor-alpha, and they had to have a couple of prior lines of therapy. And then they were randomized, so kind of chosen out of a hat to either be treated with mirvetuximab or with investigator's choice chemotherapy. So one of the chemotherapies we'd use standardly. And so that would be something like taxol, or liposomal doxorubicin, or topotecan. And basically, this study was comparing how well does mirvetuximab work compared to chemotherapy. And importantly, it showed that it improved survival, both progression-free survival, so how long it took before the disease started to grow again, but probably more importantly, actually improved overall survival, so how long a woman lived. And actually changed overall survival from about 16 and a half months compared to 12 months with chemotherapy. And so this was really important and demonstrated that mirvetuximab does actually impact women with ovarian cancer and actually helps women live longer. And that's really hard to do in this setting. And the other nice thing about this trial was that not only did it work well, but there are actually lower side effects with it, and so less women actually had to discontinue their treatment, and they had less what we call adverse events, or basically bad things that had happened from the treatment themselves. So just telling us that this drug is actually well tolerated. Women feel well on it, even when their cancer is shrinking. So I think that was one of the most impactful studies in ovary cancer. Moving on to endometrial cancer. We recently had 2 studies, one called RUBY and one called GY018 that looked at using immunotherapy in combination with chemotherapy in endometrial cancer. And what was presented at ASCO was some follow-up from this RUBY trial, which was basically validating that this combination of adding immunotherapy actually helped. To give you a background, traditionally, women that have endometrial cancer that is advanced staged, meaning spread outside of the uterus itself or has come back, we treat it with chemotherapy. But this study added an immunotherapy called dostarlimab in combination with our standard chemotherapy and actually showed that women were living longer with this, at least in that progression-free survival. We're still waiting on final evaluation. But at ASCO, what they reported was another independent blinded review of the data to show that even when we're really carefully looking at this data, it looks like immunotherapy helps women with endometrial cancer live longer. They also presented quality-of-life data showing that women actually feel better with the addition of the immunotherapy. So I think this is practice changing. And again, this data has been coming out over the last year or so, but I do think this will change the way in which endometrial cancer is treated. And then the final thing I wanted to discuss would be in cervix cancer. And while there wasn't a lot of new data presented here in terms of kind of paradigm shifts or large changes, we did have final survival [data] from the KEYNOTE-826 presented, which is also using immunotherapy along with chemotherapy in cervix cancer. And so this was in women that, again, had advanced-stage cervix cancer. So it was a cervix cancer that had moved beyond the cervix itself or cervix cancer that had come back and was treated with chemotherapy along with another immunotherapy called pembrolizumab. And this was the final survival data that confirmed that the immunotherapy did help women live longer. The survival data was impressive with about a 10-month improvement in overall survival. So how long a woman lived. And so that was really confirmatory of the previous trials. So again, that emphasizes that immunotherapy is moved towards the standard of care in cervix cancer as well. I can't hit all the highlights of the impressive research coming out of ASCO 2023, this is a brief summary of some of the critical studies in gynecologic cancers. ASCO: Thank you, Dr. Coffman. Next, Dr. Sagar Lonial discusses new research in multiple myeloma. Dr. Lonial is a professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University, where he also serves as Department Chair. He is also the 2023 Cancer.Net Associate Editor for Myeloma. You can view Dr. Lonial's disclosures at Cancer.Net. Dr. Lonial: Hello, I'm Dr. Sagar Lonial from the Emory School of Medicine and the Winship Cancer Institute in Atlanta, Georgia. And today I'm going to discuss some of the really exciting research in the context of multiple myeloma that was presented at the 2023 ASCO Annual Meeting. In terms of my conflicts of interest, I have enrolled patients on many CAR T trials as well as bispecific trials from all of the different companies involved here. So, I do have some engagement with those trials. And one of the studies that I may talk about at the end came from our institution. So I was an investigator on that study as well. When I think about some of the really exciting work that was presented at ASCO this year, there are really 2 big categories of trials that I think were most exciting. And the first is CAR T-cells and moving them earlier and earlier in the disease state. And what we saw at ASCO this year was the CARTITUDE-4 study, which was a randomized phase 3 trial comparing CAR T-cells versus standard treatment in the context of first or second relapsed multiple myeloma. And this was a really important study for us to hear because we know that CAR T-cells are highly effective in the later lines of therapy. A big question at this point is, "Does their efficacy hold up in earlier lines of therapy? And how does it compare in a randomized setting against what we might normally use in that clinical context?" And what I think we were really excited to see at ASCO this year was that CAR T-cells appear to be superior to standard treatment in the context of that randomized phase 3 trial. Now, there were a few patients who were randomized to CAR T-cells who didn't get to the CAR T-cell infusion because their disease progressed in that interval. And that is a challenge that many of us deal with on a regular basis when we think about using a CAR T in a patient. But in general, the treatment was available for almost all patients. And the analysis of benefit as measured by a longer remission duration for the patients who received CAR T cells versus those who didn't was really done on what we call an intent to treat basis. And what that means is if you were randomized to the CAR T arm, even if you didn't get the CAR T, which again was a very small number of patients, you were still evaluated as if you got a CAR. And what I think that tells us is that even taking into account some of those patients who may not get there, there still was significant clinical benefit. And this is really important data for us to have insight into. We've seen this with cilta-cel in CARTITUDE-4. We'd seen similar kinds of findings in KarMMa using ide-cel as the CAR T-cell, although it does appear that the remission duration, at least when you're comparing across trials, appears to be a little bit longer for cilta-cel than what we've seen with ide-cel. But nonetheless, it suggests that even in the context of early relapse, there may be some benefit for CARs over standard therapy. Now, does this mean that CARs are going to replace standard therapy in terms of early relapse? I don't think we know the answer to that right now. I think there's a lot of information that we need to look at to really feel comfortable making that step. The other big set of data I think that we were all very excited about to see at ASCO this year were the T-cell engagers or the bispecifics. And what we saw from a number of different bispecifics was that the efficacy data looks like it continues to hold up. But what to me was really quite exciting was the idea that the T-cell engager could be highly effective even if a patient had seen prior BCMA-directed therapy. And what this means to me is that perhaps if you're progressing on a CAR T-cell, you still may have a pretty reasonable chance at a response, again, to a BCMA-directed therapy with a bispecific. The other way around may not necessarily be the same. And so I think what we learned at this meeting is that the bispecific or T-cell engagers clearly could have activity in the context of prior BCMA-exposed therapy. And I think, as a field, we need to think more about how we define what it means to be resistant to a BCMA-directed therapy. So that I think was really important and exciting and will have relevance in our daily clinical practice. We also saw updates on a different non-BCMA-directed target. So we saw updates on GPRC5D-targeted bispecifics, also known as talquetamab. What I think was really exciting here is we saw a very high overall response rate, modest infectious complications compared to what we've seen with BCMA-directed therapy.   Finally, what I want to wrap up with was a very small study addressing what I think is a pretty significant unmet medical need. And that was a trial from Dr. Nooka at my institution, where we evaluated a combination of carfilzomib with pomalidomide and dexamethasone, or KPD. And we used that specifically as maintenance in the high-risk group. And what we learned from that evaluation is that it appears for patients with high-risk disease that KPD maintenance is better than either carfilzomib and len [lenalidomide] or even bortezomib and lenalidomide, which historically has been what we're using. But there remains an unmet medical need patient population, particularly the double-hit patient population, that even with KPD still didn't have a great outcome overall. So more work for us to do down the road. But certainly, food for thought for many of those other patients that perhaps don't fit into that double-hit classic category. So I think what I've given you is a nice sort of overview of many of the exciting data that were presented at ASCO 2023. Again, go to the website to see additional ones. And thank you again for listening to this brief summary of research in myeloma updates from the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Lonial. Finally, Dr. Cristina Rodriguez discusses new research in treating head and neck cancer. Dr. Rodriguez is a medical oncologist at Seattle Cancer Care Alliance, an Associate Professor in the Division of Medical Oncology at the University of Washington, and an Associate Member for solid tumor clinical research at the Fred Hutchinson Cancer Research Center. She is also the 2023 Cancer.Net Associate Editor for Head and Neck Cancers. You can view Dr. Rodriguez's disclosures at Cancer.Net. Dr. Rodriguez: Hello, my name is Cristina Rodriguez, and today I'm going to discuss some new research focusing on head and neck cancer that was presented at our annual ASCO 2023 meeting. As part of my disclosures, my institution receives research funding from CGEN. My takeaway from this meeting was there were a few major themes represented by the research. One of them was research on uncommon cancer types, such as nasopharyngeal cancer and salivary gland cancer. The other major theme and what was exciting for me was research on groups that were typically not represented in clinical trials in head and neck cancer. These include elderly or frail patients with many other comorbid illnesses that might have excluded them from clinical trials. Another theme was research in areas outside the developed world. In other words, resource-restricted countries. There was some exciting research coming out of that. And finally, a few new agents, novel agents that looked to have activity in patients with head and neck cancer that are going to be studied further. So with that, I'm going to start with talking about research that came out of France, presented by Dr. Fayette. This was a clinical trial that focused primarily on the frail elderly population. A group that might make very difficult for one to enter clinical trial because of many different illnesses or not being fit enough. And this group, out of France, looked at a combination of immunotherapy and a gentler lower dose chemotherapy called carboplatin and paclitaxel. Interestingly, in this group, there was very encouraging results, including 71% of patients having an objective response or a reduction in the size of their tumor, and very few patients, less than 5% of patients, having toxicity that required permanent discontinuation of the drug. So I thought this study was particularly interesting and gives us physicians and patients who are in this situation some more options to use when we're in the treatment of head and neck cancer. The next study that I thought was particularly interesting came out of India and was presented by Dr. Kothari. The special thing about this study was that it asked the question of the efficacy of a very low-cost combination for patients with recurrent or metastatic head and neck cancer. It's a combination that we don't tend to use here in the United States, one that involves methotrexate, celecoxib, and erlotinib. This particular clinical trial was carried out in several sites in India, and it randomized patients to this low-cost oral regimen versus physician's choice. In other words, any type of treatment that might involve immunotherapy or antibody therapy. The main issue here being that sometimes many of these therapies are not easily accessible to patients in low-resourced situations. The investigators observed an overall survival advantage, what that means is more patients lived longer when they use the low-cost oral regimen, which was much more practical, much easier for patients to take, and had more success in improving and prolonging the lives of patients. So I thought that that was a particularly important observation. And we forget a lot of times when we're practicing in the United States that a lot of our practice patterns here may not be applicable to low-resource settings. And I think it's very exciting that research is being carried out to answer questions that are relevant to this area. The third abstract that I thought was particularly intriguing was one presented by Dr. Glenn Hanna from Dana-Farber. And it looked at a new drug called BCA101. BCA101 is an antibody that has 2 functions. It inhibits EGFR, or epidermal growth factor receptor, very commonly overexpressed in head and neck squamous cell carcinomas. And it has a dual function, which is it modulates TGFβ, which is an immunosuppressive cytokine within tumor cells. This drug was combined with pembrolizumab in this small study and offered to patients who have never received treatment for recurrent or metastatic head and neck cancer. There was a lot of enthusiasm for this drug because in the 33 patients enrolled in the trial, 48% of them had an objective response, meaning a reduction in the size of their tumor. Anemia was one of the more common side effects that were noted. But the efficacy of this agent in this population, these patients expressed PD-L1 or had a CPS score of 1, was enough to support further study of this drug and a larger clinical trial is going to be carried out looking to see if this drug will have similar efficacy or better efficacy in a larger population. Finally, the last abstract is one that was presented by Dr. Swiecicki. And it was an interesting abstract to me because it examined the activity of another novel agent not FDA-approved for head and neck cancer, called enfortumab vedotin. This is a class of drugs that belong to a group called antibody-drug conjugates. This is an antibody that's directed toward the target called Nectin-4 and has a small chemotherapy payload that's attached to the antibody. Unlike Dr. Hanna's study, this study was a small phase 2 trial that focused on patients who've previously been treated in the recurrent or metastatic setting and are now receiving this drug either as their second or third option after they developed recurrent or metastatic disease. 46 patients were enrolled in this trial, and 24% of patients had an objective response or reduction in the size of this tumor. Although that number doesn't seem very high, it is an encouraging signal because in patients who previously received treatment for head and neck cancer, we tend to see very poor response rates. So this is encouraging given the population that was studied. Another 32% of these patients had what's called stable disease or no significant change in the size of their tumor. So that too is quite encouraging. This drug is going to also move on for further study in head and neck cancer. So I thought that these themes really brought about a lot of excitement for me for the future of treatments in patients with head and neck cancer, not only in developed countries but also in resource-restricted environments. And I look forward to next year and more work being done in these areas. And I'd like to thank you for listening to this brief summary of developments and head and neck cancer presented in the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Rodriguez. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Villa Mirasol llega a los 117 años de vida el próximo 3 de agosto, pero trasladará los festejos al domingo 6, oportunidad en la que se concretará un evento cultural y musical en el parque municipal. Lucas Laguna, actual secretario de Gobierno y futuro intendente, en diálogo con la Agencia Provincial de Noticias brindó detalles sobre el programa para esa fecha tan especial y repasó las acciones concretadas durante la gestión de Ariel Castaldo, actual intendente municipal, destacando “una continuidad de Gobierno”.“El jueves 3 de agosto es el cumpleaños 117 de Villa Mirasol, los festejos centrales serán el 6 de agosto en el Parque totalmente reacondicionado con nuevos baños, escenarios, se han cambiado los juegos, adaptados para que la gente pueda pasar un lindo domingo en ese lugar y en el cual hemos venido realizando ya algunos eventos. Ese parque es el lugar ideal para festejar nuestro cumpleaños al aire libre si el tiempo acompaña”, comentó el secretario de Gobierno.“Estarán actuando Joaquín Chavarino, el ballet Mamull Mapu, de Santa Rosa, que dirige Oscar Llanos, en lo que respecta al folclore, y la parte cuartetera a cargo de Mauro Rey. La idea es comenzar las actividades alrededor de las 14:00, para aprovechar las horas de sol y la feria de artesanos cuya inscripción está abierta para los interesados, los alumnos y alumnas del colegio secundario tendrán una cantina con todo lo necesario y poder juntar dinero para su viaje de egresados”, agregó.

In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including:ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab maintenance in primary advanced or recurrent endometrial cancer outcomes by BICRCCTG CX.5-SHAPE: phase III trial of radical hysterectomy and pelvic node dissection compared with simple hysterectomy and pelvic node dissection in low-risk, early-stage cervical cancer Final OS results from KEYNOTE-826: phase III study of CT with or without pembrolizumab as first-line treatment for patients with persistent, recurrent, or metastatic cervical cancerDUO-O: a randomized, placebo-controlled phase III study of durvalumab plus carboplatin, paclitaxel, and bevacizumab and then maintenance bevacizumab, durvalumab, and olaparib in patients with newly diagnosed advanced ovarian cancer and no BRCA1/2 gene alteration MIRASOL: an initial report from a phase III study of mirvetuximab soravtansine vs investigator's choice of CT in platinum-resistant ovarian cancer with high expression of FRαPatient-reported outcomes from the phase III ENGOT-EN6/RUBY trial of dostarlimab plus standard-of-care CT in primary advanced or recurrent endometrial cancerPresenters:Kathleen Moore, MD, MSAssociate Director, Clinical ResearchDepartment of Gynecologic OncologyStephenson Cancer Center, University of OklahomaOklahoma City, OklahomaNicoletta Colombo, MD, PhDAssociate Professor of Obstetrics and GynecologyEuropean Institute of OncologyUniversity of Milan-BicoccaMilan, ItalyContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: bit.ly/43Q5CBI

Ritu Salani, MD, and Tanios S. Bekaii-Saab, MD, FACP, spoke with CancerNetwork® about key findings presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, and how they may affect clinical practice for gynecologic cancer and gastrointestinal cancer. Salani, the Gynecologic Oncology Fellowship Director at University of California Los Angeles (UCLA) Health and the Gynecologic Oncology editorial board member for the journal ONCOLOGY®, discussed presentations on the treatment of ovarian cancer and other gynecologic malignancies. These included data on dostarlimab-gxly (Jemperli) in advanced or recurrent endometrial cancer in the phase 3 RUBY trial (NCT03981796), mirvetuximab soravtansine-gynx (Elahere) in folate receptor alpha–high platinum-resistant ovarian cancer in the phase 3 MIRASOL trial (NCT04209855), and a bevacizumab (Avastin)-based regimen in newly diagnosed ovarian cancer in the phase 3 DUO-O trial (NCT03737643). Bekaii-Saab, leader of the Gastrointestinal Cancer Program at the Mayo Clinic Comprehensive Cancer Center; medical director of the Cancer Clinical Research Office; vice chair/section chief for Medical Oncology, Department of Internal Medicine, at Mayo Clinic, Phoenix, Arizona; and the Gastrointestinal Cancer chair for the ONCOLOGY® tumor board, detailed findings from presentations in the gastrointestinal cancer space. He discussed data on fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive metastatic colorectal cancer (CRC) in the phase 2 DESTINY-CRC02 study (NCT04744831), sotorasib (Lumakras) in advanced solid tumors with KRAS G12C mutations in the phase 1b/2 CodeBreaK 101 trial (NCT04185883), and bevacizumab plus atezolizumab (Tecentriq) in metastatic CRC in the phase 2 AtezoTRIBE trial (NCT03721653). Don't forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Ovarian, cervical and endometrial cancer need more treatment options. Platinum-based chemotherapy only works for so long. ASCO 23 delivers with the practice-changing MIRASOL study introducing Mirvetuximab Soravtansine, a novel ADC with efficacy in ovarian cancer. Michael and Josh also discuss the Oval Study (ofranergene obadenovec) and immunotherapy in the DUO-O trial and Keynote 826. Not all trials are equal, and this OftIM ASCO special explores endpoints, hazard ratios and comparisons.Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.Studies:MIRASOL: https://meetings.asco.org/abstracts-presentations/226803OVAL: https://meetings.asco.org/abstracts-presentations/218323DUO-O: https://meetings.asco.org/abstracts-presentations/220048Keynote-826: https://meetings.asco.org/abstracts-presentations/220048Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sat down with the glass ceiling breaking, mover, shaker, and all things epitomizing a PGA Professional, Past President of the PGA of America and President, Golf Nation - Suzy Whaley. Host Mark Roe from TSN chats with Suzy about evolutions she has seen in the role of a PGA Professional, being a role model for young women in the profession of golf and what ally's to do to create a more inclusive environment. They also discuss how Suzy has been able to navigate a hectic schedule and what PGA professionals can do in today's burnout type world, how PGA professionals can be at the helm of retaining golfers post-COVID, making golf a more viable employment opportunity for today's youth and incoming workforce, and disruptions currently facing the golf industry. That and so much more with the one and only, Suzy Whaley.   About Suzy Whaley he first woman ever elected to serve as an Officer of the PGA of America, PGA President and PGA Master Professional Suzy Whaley is the PGA Director of Instruction for the Country Club at Mirasol in Palm Beach Gardens, Florida. She is also the PGA Director of Instruction for Suzy Whaley Golf. After serving two years as PGA Secretary, and two years as Vice President, Whaley was elected as the PGA of America's first female President at the PGA Annual Meeting in November 2018. Recognized in 2019 as one of GOLF's “Top 100 Teachers in America,” Whaley's resume includes: Golf Digest Top 50 Instructor LPGA Top 50 Instructor Two-time Connecticut PGA Teacher of the Year 10-time Golf Digest State Teacher of the Year U.S. Kids Golf Master Kids Teacher She is a five-time PGA Jr. League Championship finals Coach and has instructed more than 300 children to collegiate golf. Previously, she enjoyed a five-year tenure at Jim Flick Golf Schools, before becoming the Head Golf Professional at Blue Fox Run in Avon, Connecticut, in 2002. From 2004-06, she worked as an LPGA golf commentator for ESPN, and began her own instruction and coaching business, Suzy Whaley Golf, after ESPN. A dual member of the PGA of America and LPGA Teaching & Club Professional division, Whaley was an LPGA Tour member in 1990 and 1993. She famously qualified and participated in the 2003 Greater Hartford Open, becoming the first woman since Babe Zaharias in 1945 to qualify for a PGA Tour event. This occurred after Whaley became the first PGA of America woman professional to win the Connecticut PGA Championship. Whaley also is a three-time Connecticut Women's Open Champion; National LPGA Teaching & Club Professional winner; Connecticut PGA Section Champion; Connecticut PGA Club Professional Champion; and a two-time LPGA Northeast T&CP Section Champion. She competed in both the 2002 and 2005 PGA Professional Championships. Whaley also recently competed in the USGA Senior Women's Open, as well at the LPGA Senior Women's Championship. A 2016 Greater Syracuse Sports Hall of Fame inductee, Whaley also serves on both the ANNIKA Foundation Board and the PGA Tour Policy Board. In addition, she is an Honorary Director for the First Tee of Connecticut. Whaley was honored with the 2017 Betsy Rawls Award from the American Junior Golf Association for her service, dedication and contributions to women's golf. She was also named a 2015 Sports Business Journal “Game Changer,” cited as a woman leader who has had a major impact on sports business. Whaley also received the 2015 Margo Dydek Award from the WNBA's Connecticut Sun, for her ability to engage, challenge and inspire, while serving as a role model. A 1989 graduate of the University of North Carolina with a Bachelor's Degree in economics, Whaley and her husband, Bill, are both PGA Members. Bill is the National Director of Golf for the PGA Tour Properties Division. They have two daughters, Jennifer and Kelly.

Ezequiel Rosso, parte de Belgrano de Villa Mirasol pasó por el aire de Radio 5 para hablar sobre la actualidad de la institución y a su vez para contar más detalles sobre su nueva cancha de pádel.

Con la presencia de artistas de nivel nacional como Lisandro Márquez, presencia de carrozas y un gran concurso de disfraces, se viene una de las noches más esperadas para los vecinos de "la villa". Silvana Gette parte de la organización que está llevando adelante la organización de este festival, pasó por el aire de 5xSemana para hablar sobre los preparativos y las expectativas puestas en el fin de semana.

Got an opinion? If you're listening on the iHeartRadio app, tap the red microphone icon to record & send us your thoughts. Don't have the app? Get it free here ---> https://news.iheart.com/apps/ Follow WGY on social media: instagram.com/wgyradio twitter.

Suzy Whaley was recently elected as the President of Golf Nation, an online and connected TV/OTT channel that brings golf lifestyle and premium video together on a shoppable streaming content platform. As the first woman ever elected to serve as an officer of the PGA of America, Whaley is applying her expertise to create a more accessible, diverse, and engaging space not only in Golf but the entire sporting world. Whaley has dedicated her career to moving the Golf industry forward through a variety of roles, including Director of Instruction at the Country Club at Mirasol in Palm Beach Gardens, a PXG Ambassador, and a golf analyst and on-course commentator for ESPN, ESPN+, and SiriusXM.

This episode is a conversation with Samantha Suppiah, Christina Mirasol Sayson, Anna Denardin and Nolita Mvunelo of Possible Futures.  We talk about colonialism and sustainability, the realities of life in the Global South and the need for communities to be able to define their own vision for a regenerative future.Note: This episode is pretty heavy and may be challenging for listeners in the Global North, who are not used to considering colonialism. I invite you to stick with it and keep an open mind. This is a really important discussion.Footnotes:In the 37th minute there is a reference to "2 degrees Centigrade".  Climate scientists typically refer to temperature in Celsius in discussing climate change. Celsius is interchangeable with Centigrade.  In the 41st minute there is a reference to "10 million people dying from climate emergencies" - there is actually no current consensus estimate on how many people will die at a temperature rise of 2 deg C.  This is speculation only.  What we do have is a consensus estimate of mass migrations: for every degree increase, 1 billion migrants.  The entire issue of mass migration has notably been omitted from IPCC's Sixth Assessment Report (2022).Find out more about Possible Futures: https://www.possiblefutures.earth/ Contact the Green Urbanist: https://greenurbanistpod.com/contact Follow the Green Urbanist: https://twitter.com/GreenUrbanPod https://www.instagram.com/greenurbanistpod https://www.linkedin.com/company/green-urbanist-podcast 

Featuring a slide presentation and related discussion from Dr David O'Malley, including the following topics: Updates on ovarian cancer from the 2022 SGO Annual Meeting on Women's Cancer (0:00) Updates from clinical trials evaluating PARP inhibitors alone or in combination as neoadjuvant, adjuvant and maintenance therapy (7:25) Emerging data and ongoing clinical trials with novel agents: SORAYA, MIRASOL, PICCOLO, UpRi, UPLIFT, UPGRADE and UP-NEXT (16:10) CME information and select publications

Subcomisario Cristian Ávila; Procedimientos en General Pico por hechos ilícitos ocurridos en Villa Mirasol

In this episode, Mark Mirasol talks about opening a venue after a road trip, the similarities between competing in tennis and axe throwing, competing at a high level, and more. Photo Credit: Jesse Hummel from Throvv (https://www.instagram.com/throvvllc)

Today I am joined by Ana and Lizet. They are the founders of Mirasol Accessories which sells unique leather accessories inspired by the colors and flowers of Mexico.  Each item is handmade by expert artisans in Leon, Guanajuato - Mexico's leather capital. They hope that each piece inspires their customers to MIRAR -AL-SOL (look for the sunshine in everyday!) wherever they go. Tune in to learn more about how these ladies met, decided to start a Leather Goods business and what their journey has been like so far! Follow Mirasol Accessories IG: https://www.instagram.com/mirasolaccessories/ Facebook: https://www.facebook.com/mirasolaccessories/ Website: https://www.mirasolaccessories.com Follow Werk Mija on Social Media Instagram: @werkmija Facebook: @werkmija TikTok: @werkmija www.werkmija.com Music by: The Rewrites

With the holiday season in full swing, there's going to be a lot of opportunity for online fraud during e-commerce transactions. “Merchants are so focused on growing as quickly as possible, that they forget to put the right fraud tool,” said James L. Melon, country manager of fraud prevention services company Vesta. “The need is [only] realized when they get exposed from fraud attacks. Merchants make up for this by selling more volume, but it's like pouring more water into a leaky bucket.” In this B-Side episode, Mr. Melon tells BusinessWorld reporter Patricia B. Mirasol about reputational risks and red flags that online merchants should watch out for. Recorded remotely on Nov. 9. Produced by Paolo L. Lopez and Sam L. Marcelo.

A percentage of those who recover from coronavirus disease 2019 (COVID-19) still suffer from long COVID, a condition characterized by symptoms such as chronic fatigue, shortness of breath, and cognitive dysfunction. Initiatives such as the global AFTERCOR study, a two-year research program on the long-term outcomes of COVID-19 ICU (intensive care unit) survivors, are gathering data from its partner institutions to gain a better understanding of the medical condition's mechanism. “What's quite peculiar with COVID-19 is that it's such a chameleon,” says Dr. Karin Wildi, an Australia-based ICU specialist and principal investigator of the AFTERCOR study. In this B-Side episode, Dr. Wildi tells BusinessWorld reporter Patricia B. Mirasol how the virus attacks every organ in the body. Recorded remotely before the Omicron variant (first reported to the World Health Organization from South Africa on Nov. 24) was classified as a variant of concern by the World Health Organization on Nov. 26. Produced by Paolo L. Lopez and Sam L. Marcelo.

Mirasol President Timothy Heenan joined Steve Darling from Proactive to share news about a number of the company's projects. Heenan shared the news that drilling has started at their partnered project Gorbea. Heenan also shared details the company is preparing for a maiden ground exploration program at their Sobek project following up on the recent magnetic features identified. The company is also conducting a deep-penetrating geophysical survey at the Sascha Marcelina project which Heenan says will lead to a drilling program.

Mirasol Resources President Timothy Heenan joined Steve Darling from Proactive to introduce their project Sobek which is located in Chile. Heenan telling Proactive this project is very interesting because of its location and the recent significant discoveries at the neighbouring Filo del Sol project.

320 KBs... dnb @ DJ Глюк 1. Blvck Cvrnvge feat. dontxlook - Забери Меня с Собой 2. Ozma - Fantasy 3. Brain Wave & Vecster - Battlefield 4. Max Shade - Signals 5. Mewone - Rising 6. D-Sabber - Tomorrow Day 7. 22 - Я Тебя Игнорю 8. Nelver & Mage - Freefall 9. Luk - 70's Dances 10. INSPIRA - Ignite 11. Black Ace - None Above The Law (feat. Mirasol, Anton Platonov) 12. Gancher, Ruin - Wake Up 13. Ozma - Legendary Weapon 14. Maztra - Enough 15. Allumino — Coffee Shop (feat. Aguilaru) 16. Децл - Письмо (Rust Light bootleg)

GFA356. Today's show is featuring an old friend - Mirasol whom I met in Shenzhen back in 2010 era. She is a talented artist and musician and has been pursuing her passion and dreams of music and art for as long as I've known her. She talks about her journey in building her career in Asia. Let's tune in. For full show notes, check out GlobalFromAsia.com/artist-travels/. The post Building an Art and Music Business as a Filipina In China and Vietnam with Mirasol Aguila appeared first on Global From Anywhere.

GFA356. Today's show is featuring an old friend - Mirasol whom I met in Shenzhen back in 2010 era. She is a talented artist and musician and has been pursuing her passion and dreams of music and art for as long as I've known her. She talks about her journey in building her career in Asia. Let's tune in. For full show notes, check out GlobalFromAsia.com/artist-travels/. The post Building an Art and Music Business as a Filipina In China and Vietnam with Mirasol Aguila appeared first on Global From Asia.

El clásico más importante de Uruguay se disputó en la Copa Sudamericana. Un juego totalmente diferente para ambas instituciones. Peñarol ganó la ida y el Nacional ganó la vuelta, pero el gol de visita le da el pase a el Mirasol. Sergio Gorzy y su micrófono celeste te dan todos los detalles del clásico uruguayo en “futvox Uruguay”, un contenido exclusivo de futvox. Learn more about your ad choices. Visit megaphone.fm/adchoicesSee omnystudio.com/listener for privacy information.

A fictional eerie story that will send shivers up your spine.

Saint of the Day for January 22 Saint Vincent of Zaragossa( d. c. 304) Reflection The martyrs are heroic examples of what God’s power can do. It is humanly impossible, we realize, for someone to go through tortures such as Vincent had and remain faithfu